JZB Biotechnology

JZB Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, dedicated to the development of innovative RNA interference (RNAi) therapeutics. The company utilizes its proprietary RISE platform to design and optimize small interfering RNA (siRNA) candidates with high potency and stability. JZB's pipeline is primarily focused on chronic diseases with significant unmet needs, including cardiovascular, metabolic, and infectious diseases. Its lead programs, JZB-32 and JZB-33, target Factor XI and ANGPTL3 respectively, aiming to provide long-acting treatment options for thrombosis and dyslipidemia. By leveraging advanced liver-targeting delivery technologies, JZB Biotechnology seeks to establish itself as a leader in the global RNA medicine landscape.